This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Metsera calls Novo Nordisk $9.1bn proposal 'Superior'

( October 30, 2025, 14:44 GMT | Official Statement) -- MLex Summary: Metsera announced that its board of directors has declared an unsolicited proposal from Novo Nordisk for a total of approximately $9.1 billion to be a "Superior Company Proposal," as defined in Metsera's merger agreement with Pfizer. Under the terms of the Pfizer merger agreement, the notice of the superior proposal "triggers a four business day period during which Pfizer has the right to negotiate with Metsera adjustments to the terms and conditions of the Pfizer Merger Agreement so that the Novo Nordisk Proposal would cease to constitute a Superior Company Proposal," Metsera said.Statement follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login